Innovative Advances in CMT-SORD: Applied Therapeutics Updates
Innovative Findings from the INSPIRE Trial of Govorestat In an exciting development for patients affected by Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD), Applied Therapeutics, Inc. (Nasdaq: APLT) recently unveiled the latest clinical results of their investigational treatment, govorestat (AT-007). This biopharmaceutical company dedicated to rare...
Continue Reading